Time to abandon CAR-T monotherapy for solid tumors

Yin, Lu; Wan, Zhengwei; Sun, Ping; Shuai, Ping; Liu, Yuping

doi:10.1016/j.bbcan.2023.188930

Cited by 5 publications

(3 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of CAR-T cells with other therapeutic modalities has demonstrated potential for improved efficacy and safety. 55 commonly employed therapies such as chemotherapy, radiotherapy, and immune checkpoint inhibitors have been investigated in conjunction with CAR-T cell therapy. Chemotherapy has long been recognized as a crucial approach in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Miao,

Zhang,

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

CAR-T cell therapy has emerged as a significant approach for the management of hematological malignancies. Over the past few years, the utilization of CAR-T cells in the investigation and treatment of solid tumors has gained momentum, thereby establishing itself as a prominent area of research. This descriptive study involved the retrieval of articles about CAR-T cell therapy for solid tumors from the Web of Science Core Collection (WoSCC) database. Subsequently, bibliometric analysis and knowledge map analysis were conducted on these articles. The field under consideration is currently experiencing a period of swift advancement, as evidenced by the escalating number of publications in this domain each year. The United States holds an indisputable position as the foremost leader in this particular field, with the University of Pennsylvania emerging as the most active institution. The authors with the highest citation frequency and co-citation frequency are Carl H. June and Shannon L. Maude, respectively. The research hotspots in this field mainly focus on five aspects. Additionally, 10 emerging themes were identified. This study undertakes a comprehensive, systematic, and objective analysis and exploration of the field of CAR-T cell treatment for solid tumors, utilizing bibliometric methods. The findings of this study are expected to serve as a valuable reference and enlightenment for future research endeavors in this particular domain.

show abstract

Section: Discussionmentioning

confidence: 99%

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Miao,

Zhang,

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Additionally, CAR-T cells have limited effectiveness in treating solid tumors. Consequently, researchers have endeavored to enhance both the efficacy and safety of the therapy by optimizing CAR structure or employing combination therapies ( 8 , 9 ), such as combined radiotherapy ( 10 ), chemotherapy ( 11 ), immune checkpoint inhibitor ( 12 ), and oncolytic virus ( 13 ). These strategies have demonstrated some improvement in the effectiveness and safety of CAR-T cells; however, they have not fully resolved the aforementioned issues.…”

Section: Introductionmentioning

confidence: 99%

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Tao,

Han,

Bai

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CAR-T cell therapy, a novel immunotherapy, has made significant breakthroughs in clinical practice, particularly in treating B-cell-associated leukemia and lymphoma. However, it still faces challenges such as poor persistence, limited proliferation capacity, high manufacturing costs, and suboptimal efficacy. CRISPR/Cas system, an efficient and simple method for precise gene editing, offers new possibilities for optimizing CAR-T cells. It can increase the function of CAR-T cells and reduce manufacturing costs. The combination of CRISPR/Cas9 technology and CAR-T cell therapy may promote the development of this therapy and provide more effective and personalized treatment for cancer patients. Meanwhile, the safety issues surrounding the application of this technology in CAR-T cells require further research and evaluation. Future research should focus on improving the accuracy and safety of CRISPR/Cas9 technology to facilitate the better development and application of CAR-T cell therapy. This review focuses on the application of CRISPR/Cas9 technology in CAR-T cell therapy, including eliminating the inhibitory effect of immune checkpoints, enhancing the ability of CAR-T cells to resist exhaustion, assisting in the construction of universal CAR-T cells, reducing the manufacturing costs of CAR-T cells, and the security problems faced. The objective is to show the revolutionary role of CRISPR/Cas9 technology in CAR-T cell therapy for researchers.

show abstract

“…Cancer stands as one of the primary factors leading to mortality and imposes an increasing burden on public health (1,2). While cancer treatment has made significant progress in recent years, particularly in immunotherapy (3,4) such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell therapy (CAR-T), patient response to immune checkpoint blockade remains disappointing (5)(6)(7), and the effectiveness of CAR-T therapy on solid tumors is still unsatisfactory (8). Currently, it is understood that T cell dysfunction is a significant factor contributing to resistance to immunotherapy (9,10).…”

Section: Introductionmentioning

confidence: 99%

Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer

Yang,

Du,

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionOAS1(2’-5’-oligoadenylate synthetase 1) is a member of the Interferon-Stimulated Genes which plays an important role in the antiviral process. In recent years, the role of OAS1 in tumors has attracted attention, and it was found to be associated with prognosis in several tumors. However, the mechanism by which OAS1 affects tumors is unclear and pan-cancer study of OAS1 is necessary to better understand its implication in cancers.MethodsThe expression, prognostic value, genetic alteration, alternative splicing events of OAS1 in pan-cancers were analyzed using TCGA, GTEx, HPA, GEPIA and OncoSplicing databases. OAS1 associated immune cell infiltration was evaluated using the ESTIMATE, xCell, CIBERSORT and QUANTISEQ algorithm. Single cell transcriptome data download using TISH database. Finally, the roles of the OAS1 on apoptosis, migration and invasion were investigated in two pancreatic cancer cells.ResultsOur results revealed significant differences in OAS1 expression among various tumors, which had prognostic implications. In addition, we investigated the impact of OAS1 on genomic stability, methylation status, and other factors across different types of cancer, and the effects of these factors on prognosis. Notably, our study also demonstrated that OAS1 overexpression can contribute to CTL dysfunction and macrophage M2 polarization. In addition, cell experiments showed that the knockdown of OAS1 could reduce the invasive ability and increased the apoptosis rate of PAAD cells.DiscussionThese results confirmed that OAS1 could be a prognostic biomarker and therapeutic target for its potential role in CTL dysfunction and macrophage M2 polarization.

show abstract

Time to abandon CAR-T monotherapy for solid tumors

Cited by 5 publications

References 114 publications

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer

Contact Info

Product

Resources

About